Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	14.40B +346.2%
Revenue (ttm)	1.56B +12.8%
Net Income	112.17M +51.6%
EPS	0.50 +47.6%
Shares Out	220.49M
PE Ratio	130.62
Forward PE	n/a
Dividend	0.05 (0.08%)
Ex-Dividend Date	Jun 25, 2025

Volume	62,109,220
Average Volume	66,467,467
Open	61.26
Previous Close	60.12
Day's Range	59.85 - 65.30
52-Week Range	13.34 - 65.30
Beta	-0.37
RSI	77.51
Earnings Date	Apr 25, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,404
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.